Accurate risk stratification is critical to the clinical management of prostate cancer. The objective of our study is to investigate the effectiveness of MR molecular imaging of EDB-FN for non-invasive localization and characterization of prostate cancer aggressiveness. An EDB-FN targeting Gd-based contrast, ZD2-Gd(HP-DO3A), was designed and synthesized. Molecular MRI of EDB-FN with ZD2-Gd(HP-DO3A) can specifically improve contrast enhancement in high-risk prostate tumors, not low-risk tumors, enabling accurate characterization of prostate cancer aggressiveness. Molecular MRI with the contrast agent has great promise for detection of high-risk prostate cancer, and non-invasive differential diagnosis and risk stratification of human prostate cancer.